AEGiS-HEPP: Clinically Significant Drug Interactions Associated with Highly Active Antiretroviral Therapy

Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.

Clinically Significant Drug Interactions Associated with Highly Active Antiretroviral Therapy

John J. Faragon, PharmD, Assistant Professor of Pharmacy Practice, Albany College of Pharmacy Clinical Pharmacist Albany Medical College ^* ,
Peter J. Piliero, M.D., Associate Professor of Medicine, Albany Medical College, Clinical Consultant, New York State Department of Corrections^**

HIV Education Prison Project: Volume 7, Number 1 - January 2004

One of the most challenging issues facing providers treating patients with human immunodeficiency virus - 1 (HIV) infection is the complex problem of drug interactions associated with highly active antiretroviral therapy (HAART). Guidelines for the initial treatment of HIV infection recommend the use of at least three antiretroviral medications, each of which is associated with significant drug interactions.1 Further increasing the risk of drug interactions is the concurrent treatment of co-morbid disease states and therapies for prevention and/or treatment of opportunistic infections (OIs). This review focuses on the clinically significant drug interaction associated with the use of HAART.

Drug Interaction Overview

Table 1

HIV 101

**Speakers fees : Abbott, Agouron (Pfizer), and GlaxoSmithKline, Consultant fees: Roche and Gilead

**Honoraria: BMS, Abbott, GSK, Roche, Merck, Gilead, Research: GSK, Roche, Trimeris, Pfizer, Boehringer-Ingelheim, Gilead

1. .

2. .

3. .

4. .

5. .

6. .

7. .

8. .

9. .

10. .

11. .

12. .

13. .

14. .

040201
HEPP2004-0201

©1997,1998,1999,2000,2001,2002, 2004. The recently formed HIV Education Prison Project (HEPP) is a medical education program that targets a growing population, inmates in correctional facilities, that has been underserved in HIV care. It is part of the Brown University AIDS Program. Permission to use and reproduce portions of this newsletter is hereby granted provided that author and publication are fully credited and both copyright and permission notice appear with reprinted material. Inquiries may be directed to heppnews@brown.edu. Website: HIV Education Prison Project.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.